The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
复制标题
DOI：
10.1056/nejm199608223350801
复制
发表时间：
1996-08-22
影响因子：
158.5
通讯作者：
Padley, RJ
中科院分区：
文献类型：
--
作者：
Lepor, H;Williford, WO;Padley, RJ
背景 患有良性前列腺增生的男性可以使用可松弛前列腺平滑肌的 α(1)-肾上腺素能拮抗剂药物或抑制 5α-还原酶从而降低组织雄激素浓度的药物进行治疗。然而，尚未比较两类药物的效果。方法我们在 1229 名患有良性前列腺增生的男性中比较了安慰剂、特拉唑嗪（每天 10 毫克）、非那雄胺（每天 5 毫克）以及两种药物联合用药的安全性和有效性。美国泌尿外科协会的症状评分和峰值尿流率在基线和一年内定期进行测定。结果安慰剂组、非那雄胺组、特拉唑嗪组和联合治疗组的症状评分在一年内相对于基线的平均变化分别降低了 2.6、3.2、6.1 和 6.2 分（P
Background Men with benign prostatic hyperplasia can be treated with alpha(1)-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared.Methods We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year.Results The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P